1 / 18

A major new international research initiative

Presented by . Martin J Brodie on behalf of the EUCARE Management Group. A major new international research initiative . EUCARE is a joint initiative of the ILAE and IBE supported by an unrestricted educational grant from UCB Pharma.

gram
Télécharger la présentation

A major new international research initiative

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Presented by Martin J Brodieon behalf of theEUCARE Management Group A major new international research initiative EUCARE is a joint initiative of the ILAE and IBE supported by an unrestricted educational grant from UCB Pharma

  2. FONDE STUDY Health burden of epilepsy • Around 5-10% of people will have a seizure at some time in their lives, 30% of whom will go on to develop epilepsy • Thus 1% of the world’s population will have epilepsy at any given point in time, amounting to a total of 40 million • 30-40% of people with epilepsy will have uncontrolled seizures accounting for over 80% of the overall cost • This represents 1% of the Global Burden of Disease (WHO) • and is equivalent to - breast cancer in women • - lung cancer in men

  3. NEWLY DIAGNOSED EPILEPSY Epilepsy wheel of fortune Intolerable side-effects Vagal nerve stimulation Seizure-free Refractory Surgery

  4. EARLY IDENTIFICATION OF REFRACTORY EPILEPSY Patrick Kwan and Martin J Brodie Epilepsy Unit, University Department of Medicine & Therapeutics Western Infirmary, Glasgow, Scotland February 3, 2000; 342: 314-319

  5. MEDIAN AGE 29 YEARS (RANGE 9-93) MEDIAN FOLLOW-UP 6.6 YEARS (RANGE 2-21) NEWLY DIAGNOSED EPILEPSYOutcomes from July 1982 to May 2003 (N=780) • Responder – seizure-free for a minimum of 12 months • Immediate responder – no seizures after starting treatment • Remission – no relapse after becoming seizure-free • Relapse – controlled for at least one year then refractory • Non-responder – never seizure-free for any 12 months

  6. Remission (59.2%) Non-responders (35.4%) Relapse (5.4%) Immediate responders (31.4%) NEWLY DIAGNOSED EPILEPSYCategories of response to treatment(N=780) Responders (64.6%) Mohanraj R, Brodie MJ. Eur J Neurol 2006; 13: 277-82

  7. 100 80 60 40 20 0 NEWLY DIAGNOSED EPILEPSYRemission rates according to age Percentage 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ n=59 n=131 n=99 n=87 n=71 n=56 n=51 n=36 n=34 n=35 n=31 n=19 n=29 n=23 n=11 n=8 Brodie MJ, Kwan P. Br Med J 2005;331:1317-22

  8. KAPLAN-MEIR PLOT OF TIME TO RELAPSE % seizure free 1 0 0 9 5 9 0 8 5 Years of follow up 2 4 8 12 Risk of relapse (%) 4.2% 8.0% 10.4% 10.4% 8 0 Months on treatment Number relapsed Number at risk 0 1 2 2 4 3 6 4 8 6 0 7 2 8 4 9 6 1 0 8 1 2 0 0 504 14 479 36 313 40 217 42 96 42 54

  9. OUTCOMES BY NUMBER OF PRE-TREATMENT SEIZURES % 25% 24% 39% 34% 48% 55% 100 14 20 32 30 45 50 11 Uncontrolled 4 80 Relapse 4 7 Remission 60 3 5 40 p = 0.024 75 76 61 66 52 45 20 0 1 2 3 - 5 6 - 10 11 – 20 >20 (n=28) (n=149) (n=212) (n=89) (n=69) (n=233) Number of pre-treatment seizures

  10. 38% 43% 45% 47% 45% % 100 80 33 38 40 39 40 Uncontrolled 5 Relapse 5 5 8 5 60 Remission 40 62 57 5553 55 20 0 < 1 1 - 2 3 - 5 6 - 10 > 10 (n=440) (n=124) (n=105) (n=60) (n=51) Time from first seizure until starting treatment (years) OUTCOMES BY DURATION OF EPILEPSY PRIOR TO STARTING TREATMENT

  11. OUTCOMES BY NUMBER OF PRE-TREATMENT SEIZURESThree months before starting treatment % 0% 28% 38% 48% 49% 64% 100 21 32 48 45 61 80 7 Uncontrolled 6 Relapse 60 Remission 4 3 40 p < 0.001 20 100 72 62 52 51 36 0 none 1 2 – 5 6 – 10 11 – 20 >20 (n=3) (n=164) (n=335) (n=64) (n=53) (n=64) Number of pre-treatment seizures

  12. NEWLY DIAGNOSED EPILEPSYPredictors of refractoriness (multivariate analysis) Odds ratio 95% CI p value Family history 1.89 1.15-3.00 0.011 Febrile seizures 3.36 1.58-7.18 0.002 Traumatic brain injury 3.26 1.59-4.69 <0.001 Psychiatric comorbidity 2.17 1.33-3.55 0.002 Recreational drug use 4.26 2.03-8.94 <0.001 10 or more seizures 2.77 1.98-3.89 <0.001 Hitiris N et al. Epilepsy Research 2007; 75: 192-6

  13. NEWLY DIAGNOSED EPILEPSYPredictors of refractoriness (multivariate analysis) Odds ratio 95% CI p value Family history 1.89 1.15-3.00 0.011 Febrile seizures 3.36 1.58-7.18 0.002 Traumatic brain injury 3.26 1.59-4.69 <0.001 Psychiatric comorbidity 2.17 1.33-3.55 0.002 Recreational drug use 4.26 2.03-8.94 <0.001 10 or more seizures 2.77 1.98-3.89 <0.001 Hitiris N et al. Epilepsy Research 2007; 75: 192-6

  14. NEWLY DIAGNOSED EPILEPSY Follow up of 97 consecutive patients undergoing antero-temporal lobectomy • A lifetime history of depression was the sole predictor of post-surgical auras (p<0.0001) in seizure-free patients • A lifetime history of depression was also a predictor of disabling seizures with or without auras (p=0.001). Kanner AM et al, Neurology, submitted

  15. EPILEPSY MORTALITY N SMR 95% CI p value Newly diagnosed 890 1.42 1.16-1.72 p=0.0007 Chronic epilepsy 2689 2.05 1.83-2.26 p<0.0001 No increase in risk was observed in patients who were seizure-free Mohanraj R et al Lancet Neurology 2006; 5: 481-7

  16. NEWLY DIAGNOSED EPILEPSY Outcomes by syndromic classification * + * + 34% 43% 44% % Uncontrolled 100 Relapse 27 38 39 Remission 7 80 5 5 60 * p = 0.041 + p = 0.035 40 66 57 56 20 0 Idiopathic Cryptogenic Symptomatic (N=222) (N=314) (N=244) Mohanraj R, Brodie MJ. Eur J Neurol 2006;13:277-82

  17. NEWLY DIAGNOSED EPILEPSY Interictal EEG of a patient with juvenile myoclonic epilepsy showing generalised multiple spike-and-wave complexes

  18. NEWLY DIAGNOSED EPILEPSY Treatment response in juvenile myoclonic epilepsies (N=55; 25% population) Responders (70%) Remission (73%) Non-responders (20%) Relapse (7%) Immediate responders (36%) Mohanraj R, Brodie MJ. Acta Neurol Scand 2007; 115: 204-8

More Related